Section 1: The Regulatory Trinity: Anatomy of the Three Small-Molecule Pathways Why the Categorization Matters More Than Most Teams Think […]
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation Read Post »
1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of
How secondary pharmaceutical patents work, why they survive litigation, and what evergreening debates actually get wrong about post-approval R&D economics
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent
A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
1. The Pricing Crisis in Numbers The United States spends more per capita on prescription drugs than any other OECD
Precision Medicine Drug Pricing: The Complete IP, Patent, and Market Access Playbook Read Post »
A strategic guide to patent expiry, lifecycle defense, and the economics of generic competition — for executives, investors, and analysts
What Happens When a Drug Patent Expires? Understanding Drug Patent Life Read Post »
1. What a Tentative Approval Actually Means (and What It Doesn’t) A Tentative Approval (TA) letter from the FDA means
FDA Tentative Approval: The Generic Drug Strategist’s Complete Playbook Read Post »
Sign in or create a free account to read this DrugPatentWatch article
